MGMT testing for glioma in clinical laboratories: Discordance with methylation analyses prevents the implementation of routine immunohistochemistry

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 11, 2012, Pages 1789-1797

  Mason, Sofia ^a   McDonald, Kerrie ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Epigenetics; Glioblastoma; Immunohistochemistry; MGMT; Predictive markers

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANALYTIC METHOD; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL LABORATORY; DNA ADDUCT; DNA METHYLATION; DNA REPLICATION; ENHANCER REGION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; GENE EXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MGMT GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEMI QUANTITATIVE METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; STANDARDIZATION; TREATMENT RESPONSE;

EID: 84870432509     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1312-1     Document Type: Review

References (58)

1. Anda T, Shabani HK, Tsunoda K, Tokunaga Y, Kaminogo M, Shibata S, Hayashi T, Iseki M (2003) Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-trans-ferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25(3): 241-248 (Pubitemid 36520478)
2. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. doi:10.1007/s00401-012-1016-2
3. Balana C, Carrato C, Ramirez JL, Cardona AF, Berdiel M, Sanchez JJ, Taron M, Hostalot C, Musulen E, Ariza A, Rosell R (2011) Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. Clin Translat Oncol 13: 677-685
4. Blough MD, Zlatescu MC, Cairncross JG (2007) O6-Methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67(2): 580-584. doi:10.1158/0008-5472.can-06-2782 (Pubitemid 46192195)
5. Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of O6-methylguanine-DNA methyltrans-ferase determined by promoter hypermethylation and immuno-histochemical expression in Anaplastic Gliomas. Clin Cancer Res 11 (14): 5167-5174. doi:10.1158/1078-0432. ccr-05-0230 (Pubitemid 41003702)
6. Brell M, Ibanez J, Tortosa A (2011) O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 11(1):35
7. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP (2005) Years of life lost (YLL) from cancer is an important measure of population burden: and should be considered when allocating research funds. Br J Cancer 92(2): 241-245. doi:10.1038/sj.bjc.6602321 (Pubitemid 40343136)
8. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87(4): 392-397. doi: 10.1038/labinvest.3700520 (Pubitemid 46474563)
9. Cao VT, Jung T-Y, Jung S, Jin S-G, Moon K-S, Kim I-Y, Kang S-S, Park C-S, Lee K-H, Chae H-J (2009) The correlation and prognostic significance of Mgmt promoter methylation and mgmt protein in glioblastomas. Neurosurgery 65 (5): 866-875
10. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J (2008) Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol 115(2): 249-259. doi:10.1007/s00401-007-0310-x
11. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25(12): 1470-1475 (Pubitemid 46733073)
12. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, Wick W, Weiler M (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE 7(3):13
13. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19): 1350-1354. doi: 10.1056/NEJM200011093431901
14. Everhard S, Tost Jr, El Abdalaoui H, CriniÄre E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre J-Y, Thillet Jl (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro-Oncology 11 (4): 348-356. doi:10.1215/15228517-2009-001
15. Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A (2010) Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. J Neurooncol 100(2): 209-215. doi: 10.1007/s11060-010-0163-3
16. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15(21): 6683-6693
17. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121(11): 2458-2464 (Pubitemid 350022415)
18. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA (2009) Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 27(25): 4155-4161. doi:10.1200/JCO.2008.21.6895
19. Havik A, Brandal P, Honne H, Dahlback H-S, Scheie D, Hektoen M, Meling T, Helseth E, Heim S, Lothe R, Lind G (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Trans Med 10(1): 36
20. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997-1003. doi:10.1056/NEJMoa043331 (Pubitemid 40349502)
21. Jacinto FV, Esteller M (2007) MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 6(8): 1155-1160 (Pubitemid 47058396)
22. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87(10): 1055-1065 (Pubitemid 47429190)
23. Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW (2011) O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6(2):e17156
24. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2): 142-148. doi:10.1200/JCO.2010.30.2729
25. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T (2007) Novel mechanism whereby nuclear factor ΰB Mediates DNA damage repair through regulation of O6-methylguanine-DNA-methyltransferase. Cancer Res 67(18): 8952-8959. doi: 10.1158/0008-5472.can-06-3820 (Pubitemid 47437473)
26. Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS (2006) Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5(10): 2531-2539. doi:10.1158/1535-7163.mct-06-0106 (Pubitemid 44650917)
27. Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D (2009) MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genom Proteom 6(4): 219-227
28. Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115(20): 4783-4794
29. Middleton MR, Margison GP (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4(1): 37-44 (Pubitemid 36124189)
30. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Internat J Cancer 113(3): 379-385. doi:10.1002/ijc. 20575 (Pubitemid 40038704)
31. Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T (2009) Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29(4): 379-388. doi:10.1111/j.1440- 1789.2008.00983.x
32. Nakasu S, Fukami T, Baba K, Matsuda M (2004) Immunohisto-chemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70(3): 333-340 (Pubitemid 40057961)
33. Ochsenbein AF, Schubert AD, Vassella E, Mariani L (2011) Quantitative analysis of O6-methylguanine DNA methyltrans-ferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol 103(2): 343-351
34. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T (2011) The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 6(8):e23332
35. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87(1): 71-78
36. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98(1): 93-99. doi:10.1007/s11060-009-0067-2
37. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008a) Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18(4): 520-532
38. Preusser M, Elezi L, Hainfellner JA (2008b) Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27(6): 388-390
39. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118(17): 4201-4211
40. Riemenschneider MJ, Hegi ME, Reifenberger G (2010) MGMT promoter methylation in malignant gliomas. Target Oncol 5(3): 161-165
41. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, James CD, Passe S, Slezak J, Giannini C (2008) MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16(1): 59-65
42. Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32(8): 1220-1227
43. Sciuscio D, Diserens AC, van Dommelen K, Martinet D, Jones G, Janzer RC, Pollo C, Hamou MF, Kaina B, Stupp R, Levivier M, Hegi ME (2011) Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res 17(2): 255-266. doi:10.1158/1078-0432.CCR-10-1931
44. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K (2009) Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29(10): 3759-3768
45. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir 151(11): 1349-1358
46. Spiegl-Kreinecker S, Pirker C, Filipits M, Latsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, Berger W (2009) O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro-Oncol. doi:10.1093/neuonc/nop003
47. Srivenugopal KS, Shou J, Mullapudi SRS, Lang FF, Rao JS, Ali-Osman F (2001) Enforced expression of wild-type p53 curtails the transcription of the O6-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 7(5): 1398-1409 (Pubitemid 32708697)
48. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Jr Curschmann, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff R (2005a) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996. doi:10.1056/NEJMoa043330 (Pubitemid 40349501)
49. Stupp R, van den Bent MJ, Hegi ME (2005b) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Reports 5(3): 198-206 (Pubitemid 40873035)
50. Stupp R, Bent MJVD, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi M, Perry JR, Picard M, Weller M (2010a) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC). J Clin Oncol 28:15s (suppl; abstr TPS152)
51. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010b) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16): 2712-2718. doi:10.1200/JCO.2009.26.6650
52. Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK (2011) Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics 66(10): 1747-1755
53. Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L (2011) Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. J Neuro-oncol 104(1): 293-303. doi:10.1007/s11060-010-0490-4
54. Vig HS, Wang C (2012) The evolution of personalized cancer genetic counseling in the era of personalized medicine. Fam Cancer. doi: 10.1007/s10689-012-9524-8
55. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bahr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W (2010) Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 77(3): 670-676. doi:10.1016/j.ijrobp. 2009.05.031
56. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1): 39-51
57. Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67(1): 1-15
58. Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H (2009) Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32(1): 21-29